RxDoctor Payments Data

Hany Elbeshbeshy, MD

Hepatology · Saint Louis, MONPI 1376637744

Payments from drug & device makers

$854,764in general payments, 2019–2025

Across 811 payments — averaging $1053.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$159K
  • Intercept Pharmaceuticals, Inc.$147K
  • Mallinckrodt Hospital Products Inc.$127K
  • Ipsen Biopharmaceuticals, Inc$108K
  • Madrigal Pharmaceuticals$101K
  • Gilead$83K
  • plus $129K from 10 others

What the payments were for

  • Consulting fees$39,6685%
  • Speaking & faculty fees$639,65684%
  • Travel & lodging$60,9288%
  • Food & beverage$18,3762%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$78,519
Medicare patients
286
Services billed
748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid16$289,651
XifaxanRifaximin31$104,341
Ursodiol138$32,535
Envarsus XrTacrolimus24$20,940
Tacrolimus59$3,597
Entecavir21$2,357
Azathioprine17$1,301
Nadolol37$1,185
Omeprazole69$1,066
Spironolactone102$1,053
Ondansetron OdtOndansetron17$724
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl36$585
Lactulose12$429
Nifedipine ErNifedipine11$417
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl29$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$147,289$289,65116 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$97$104,34131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Missourion file to place this against a meaningful peer group, so we don't.

Other hepatology in Saint Louis

Where these figures come from

Is this you, or does something look wrong? →